In ccRCC, where resistance to TKIs and ICIs remains a major barrier to durable disease control [5,6], combining these agents with FAP-targeted therapies may provide a rational strategy to overcome stromal-mediated resistance. The gene discussed is FAP; the disease is nonpapillary renal cell carcinoma.